Champions Biotechnology, Inc. Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing

Published: Jul 16, 2009

IT News Online -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a collaboration with Do-Coop Technologies Ltd. of Israel for development of a more soluble form of SG410, its Benzoylphenylurea (BPU) sulfur analog compound. SG410, an in-licensed compound, is the first agent in Champions' drug development pipeline. Using Neowater(R), a novel proprietary water-based nanotechnology, Do-Coop has been able to improve the solubility and activity of SG410.

Back to news